

Variant: NM_007294.4(BRCA1):c.301+7G>A

Version: 2.0

CA001969 [↗](#)

37499 (ClinVar) [↗](#)

Gene: BRCA1 ([HGNC:672](#))

Condition: BRCA1-related cancer predisposition ([MONDO:0011450](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: fbbb5452-b586-4a7b-9f6b-8416630042bc

Approved on: 2024-06-12

Published on: 2024-06-11

HGVS expressions

NM_007294.4:c.301+7G>A

NM_007294.4(BRCA1):c.301+7G>A

NC_000017.11:g.43104861C>T

CM000679.2:g.43104861C>T

NC_000017.10:g.41256878C>T

CM000679.1:g.41256878C>T

NC_000017.9:g.38510404C>T

NG_005905.2:g.113123G>A

ENST00000354071.8:n.365+7G>A

ENST00000461574.2:c.301+7G>A

ENST00000470026.6:c.301+7G>A

ENST00000473961.6:c.301+7G>A

ENST00000476777.6:c.301+7G>A

ENST00000477152.6:c.223+7G>A

ENST00000478531.6:c.301+7G>A

ENST00000489037.2:c.223+7G>A

ENST00000493919.6:c.160+7G>A

ENST00000494123.6:c.301+7G>A

ENST00000497488.2:c.-218-10001G>A

ENST00000618469.2:c.301+7G>A

ENST00000634433.2:c.301+7G>A

ENST00000644379.2:c.301+7G>A

ENST00000644555.2:c.160+7G>A

ENST00000652672.2:c.160+7G>A

ENST00000484087.6:c.301+7G>A

ENST00000700083.1:n.1272+7G>A

ENST00000700182.1:c.223+7G>A

ENST00000700183.1:c.*215+7G>A

ENST00000700184.1:n.544+7G>A

ENST00000357654.9:c.301+7G>A

ENST00000471181.7:c.301+7G>A

ENST00000642945.1:c.*175+7G>A

ENST00000644555.1:c.160+7G>A

ENST00000652672.1:c.160+7G>A

ENST00000352993.7:c.301+7G>A

ENST00000354071.7:c.301+7G>A

ENST00000357654.7:c.301+7G>A

	ENST00000461221.5:c.*87+7G>A ENST00000468300.5:c.301+7G>A ENST00000470026.5:c.301+7G>A ENST00000471181.6:c.301+7G>A ENST00000473961.5:c.24+7G>A ENST00000476777.5:c.301+7G>A ENST00000477152.5:c.223+7G>A ENST00000478531.5:c.301+7G>A ENST00000484087.5:c.49+7G>A ENST00000487825.5:c.49+7G>A ENST00000489037.1:c.223+7G>A ENST00000491747.6:c.301+7G>A ENST00000492859.5:c.*237+7G>A ENST00000493795.5:c.160+7G>A ENST00000493919.5:c.160+7G>A ENST00000494123.5:c.301+7G>A ENST00000497488.1:c.-218-10001G>A ENST00000586385.5:c.4+20321G>A ENST00000591534.5:c.-44+20410G>A ENST00000591849.5:c.-99+20410G>A ENST00000634433.1:c.301+7G>A NM_007294.3:c.301+7G>A NM_007297.3:c.160+7G>A NM_007298.3:c.301+7G>A NM_007299.3:c.301+7G>A NM_007300.3:c.301+7G>A NR_027676.1:n.440+7G>A NM_007297.4:c.160+7G>A NM_007299.4:c.301+7G>A NM_007300.4:c.301+7G>A NR_027676.2:n.481+7G>A
--	---

Benign	Met criteria codes 4 BP7_StrongBS3BP5_Strong BS1_Supporting Not Met criteria codes 1 PP3 Evidence Links 0	Expert Panel ENIGMA BRCA1 and BRCA2 VCEP Criteria Specification Information Criteria Specification: ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for BRCA1 Version 1.0.0 Criteria Specification Approval History Criteria Specifications for this VCEP
-------------------	---	--

Evidence submitted by expert panel
ENIGMA BRCA1 and BRCA2 VCEP The c.301+7G>A variant is an intronic variant occurring in intron 5 of the BRCA1 gene. The highest non-cancer, non-founder population filter allele frequency in gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥20) or gnomAD v3.1 (non-cancer subset, read depth

≥20) is 0.00009711 in the European (non-Finnish) population which is within the ENIGMA BRCA1/2 VCEP threshold (>0.00002 to ≤ 0.0001) for BS1_Supporting (BS1_Supporting met). This BRCA1 intronic variant is located outside of the native donor and acceptor 1,2 splice sites, and the SpliceAI predictor score is 0.21, predicting an impact on splicing (score threshold >0.20) (however, this prediction is to strengthen the native acceptor site and therefore PP3 is not applied). This is an intronic variant, and mRNA experimental analysis indicates no impact on splicing (PMID: 22505045), considered strong evidence against pathogenicity (BP7_Strong (RNA)). Reported by one calibrated study to exhibit protein function similar to benign control variants (PMID: 30209399) (BS3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 4.848E-11 (based on Cosegregation LR=1.36; Pathology LR=0.001; Co-occurrence LR=0.068; Family History LR=0.037; Case-Control LR=1.28E-05), below the threshold for Very strong benign evidence (LR <0.00285) (BP5_Very strong met; PMID: 31131967). In summary, this variant meets the criteria to be classified as a Benign variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (BS1_Supporting, BP7_Strong (RNA), BS3, BP5_Very strong).

Met criteria codes

BP7_Strong			This is an intronic variant, and mRNA experimental analysis indicates no impact on splicing (PMID: 22505045), considered strong evidence against pathogenicity (BP7_Strong (RNA)).
BS3			Reported by one calibrated study to exhibit protein function similar to benign control variants (PMID: 30209399) (BS3 met).
BP5_Strong			Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 4.848E-11 (based on Cosegregation LR=1.36; Pathology LR=0.001; Co-occurrence LR=0.068; Family History LR=0.037; Case-Control LR=1.28E-05), below the threshold for Very strong benign evidence (LR <0.00285) (BP5_Very strong met; PMID: 31131967).
BS1_Supporting			The highest non-cancer, non-founder population filter allele frequency in gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥20) or gnomAD v3.1 (non-cancer subset, read depth ≥20) is 0.00009711 in the European (non-Finnish) population which is within the ENIGMA BRCA1/2 VCEP threshold (>0.00002 to ≤ 0.0001) for BS1_Supporting (BS1_Supporting met).

Not Met criteria codes

PP3			This BRCA1 intronic variant is located outside of the native donor and acceptor 1,2 splice sites, and the SpliceAI predictor score is 0.21, predicting an impact on splicing (score threshold >0.20) (however, this prediction is to strengthen the native acceptor site and therefore PP3 is not applied).
-----	---	---	---

Curation History 



▼

▼

Showing 1 to 2 of 2 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.